Login to Your Account



Incyte Scores Big with the Approval of First JAK Inhibitor

By Mari Serebrov
Washington Editor

Thursday, November 17, 2011
Incyte Corp. scored two firsts with Jakafi, its first product out the pipeline: It's the first JAK inhibitor approved by the FDA. And it's the first drug approved to treat the bone marrow disease myelofibrosis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription